Current Report Filing (8-k)
23 März 2020 - 1:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 23, 2020
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
Framingham, Massachusetts
|
01702
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
N|A
|
N|A
|
N|A
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On March 23, 2020, Arch Therapeutics, Inc. (the “Company”)
issued a press release announcing that the U.S. Food and Drug Administration
(FDA) provided marketing authorization related to AC5® Topical Gel Supply Chain. The text of the press release
is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The disclosure under Item 7.01 (Regulation FD Disclosure) is
incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) The following exhibits are being filed
herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
Dated: March 23, 2020
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Name:
|
Terrence W. Norchi, M.D.
|
|
|
Title:
|
President, Chief Executive Officer
|
|
|
|
|
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Arch Therapeutics Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere Arch Therapeutics, Inc. News-Artikel